Related Experiment Video
Updated: Aug 17, 2026
Indirect Immunofluorescence on Frozen Sections of Mouse Mammary Gland
Published on: December 1, 2015
Neuregulin-regulated gene expression in mammary carcinoma cells
Dhara N Amin1, David Tuck, David F Stern
1Department of Pathology, Yale University School of Medicine, BML-342, 310 Cedar Street, P.O. Box 208023, New Haven, CT 06520-8023, USA.
Abstract:
Recent studies have suggested that autocrine production of Neuregulin (NRG), a growth factor that activates members of the Epidermal Growth Factor Receptor/ErbB family of proto-oncogenes, is sufficient for breast tumor initiation and progression. To elucidate the molecular mechanisms regulating these events, we undertook a global analysis of genes regulated by NRG in luminal mammary epithelial cell lines. Gene expression profiling of estrogen receptor-positive T47D cells exposed to NRG-1 revealed both previously identified and novel targets of NRG activation. Profiling of other estrogen receptor-positive breast cancer cell lines, MCF7 and SUM44, yielded a group of twenty-one genes whose transcripts are upregulated by NRG in all three lines tested. The NRG targets are FBJ murine osteosarcoma viral oncogene homolog B, Early growth response 1, v-jun avian sarcoma virus 17 oncogene homolog, Activating transcription factor 3, Homo sapiens cDNA FLJ31636 fis, Jun B proto-oncogene, Forkhead box C1, Platelet/endothelial cell adhesion molecule 1, NADPH-dependent retinol dehydrogenase/reductase, Dual specificity phosphatase 5, NGF inducible protein TIS21, Connective tissue growth factor, Jun D proto-oncogene, Serum response factor, Cullin 1, v-myc avian myelocytomatosis viral oncogene, Transient receptor potential channel 1, Low density lipoprotein receptor, Transforming growth factor beta 1, Nucleoporin 88 kDa, and Pleckstrin homology-like domain A1. Since NRG activation of these cells induces resistance to anti-hormonal therapy, the identified genes may provide clues to molecular events regulating mammary tumor progression and hormone independence.
Insights
Neuregulin (NRG) drives breast tumor growth by activating Epidermal Growth Factor Receptor/ErbB pathways. This study identifies 21 key genes upregulated by NRG, offering insights into hormone independence and therapeutic resistance in breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Autocrine Neuregulin (NRG) signaling is implicated in breast tumor initiation and progression.
- NRG activates Epidermal Growth Factor Receptor/ErbB proto-oncogenes, crucial in cancer development.
Purpose of the Study:
- To globally analyze genes regulated by NRG in luminal mammary epithelial cells.
- To identify molecular mechanisms underlying NRG-driven breast tumor progression and hormone independence.
Main Methods:
- Gene expression profiling of estrogen receptor-positive breast cancer cell lines (T47D, MCF7, SUM44) treated with NRG-1.
- Analysis of NRG-upregulated transcripts across multiple cell lines.
Main Results:
- Identified previously known and novel NRG target genes.
- Discovered a core set of 21 genes consistently upregulated by NRG across three breast cancer cell lines.
- NRG activation induced resistance to anti-hormonal therapy in these cells.
Conclusions:
- The identified NRG target genes provide potential molecular insights into mammary tumor progression.
- These genes may play a role in the development of hormone independence in breast cancer.
- Understanding these pathways could inform therapeutic strategies against hormone-refractory breast cancer.
